David Kuter, MD
Hematology · Boston, MANPI 1457342024
Payments from drug & device makers
Across 522 payments — averaging $5943.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1M
- Agios Pharmaceuticals, Inc.$460K
- Sanofi US Services Inc.$384K
- Sanofi$256K
- Bioverativ Therapeutics Inc.$147K
- Amgen$129K
- plus $706K from 26 others
Across 74 payments — averaging $4052.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$242K
- Amgen$26K
- Sanofi$14K
- Bioverativ Therapeutics Inc.$6K
- Novartis$4K
- Novartis Pharma AG$4K
- plus $4K from 4 others
What the payments were for
- Consulting fees$369,88068%
- Speaking & faculty fees$83,83315%
- Travel & lodging$84,92216%
- Food & beverage$4,2321%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 51 | $1,020,799 |
| Agios Pharmaceuticals, Inc. | 41 | $459,541 |
| Sanofi US Services Inc. | 70 | $384,028 |
| Sanofi | 66 | $256,078 |
| Bioverativ Therapeutics Inc. | 14 | $146,653 |
| Amgen | 58 | $129,324 |
| Principia Biopharma Inc. | 20 | $114,459 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $91,827 |
| Rigel Pharmaceuticals, Inc. | 15 | $89,074 |
| Alnylam Pharmaceuticals Inc. | 21 | $89,054 |
| Incyte Corporation | 15 | $66,715 |
| Swedish Orphan Biovitrum AB | 13 | $54,588 |
| AstraZeneca | 34 | $50,043 |
| E.r. Squibb & Sons, L.L.C. | 7 | $32,469 |
| Dova Pharmaceuticals | 12 | $26,547 |
| UCB SA | 8 | $20,930 |
| Merck | 20 | $14,139 |
| Sobi, Inc | 7 | $9,331 |
| Chugai Pharmaceutical Co., Ltd. | 6 | $8,430 |
| Biocryst Pharmaceuticals, Inc. | 5 | $8,215 |
| Novartis Pharma AG | 1 | $5,502 |
| UCB, Inc. | 1 | $4,830 |
| Apellis Pharmaceuticals, Inc. | 3 | $4,607 |
| Pfizer | 3 | $4,500 |
| Vertex | 2 | $4,270 |
| Recordati_rare_diseases_inc. | 2 | $2,397 |
| Daiichi Sankyo Inc. | 1 | $1,290 |
| New York Blood Center, Inc. | 1 | $1,200 |
| Regeneron | 1 | $881 |
| Ipsen Bioscience Inc. | 1 | $580 |
| Argenx US, Inc. | 1 | $108 |
| UCB Biosciences Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,102,430 in reported general payments places this provider in the 90th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 123 | $1,936,630 |
| CerdelgaEliglustat Tartrate | 16 | $493,281 |
| DopteletAvatrombopag Maleate | 23 | $429,720 |
| ImbruvicaIbrutinib | 34 | $419,597 |
| EliquisApixaban | 96 | $129,876 |
| XareltoRivaroxaban | 72 | $95,830 |
| RetacritEpoetin Alfa-Epbx | 12 | $41,193 |
| Fondaparinux Sodium | 19 | $24,697 |
| Hydroxyurea | 135 | $4,647 |
| Prednisone | 27 | $444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $66,715 | $1,936,630123 claims |
| SanofiCerdelga | $256,078 | $493,28116 claims |
| Dova PharmaceuticalsDoptelet | $26,547 | $429,72023 claims |
| PfizerEliquis, Retacrit | $4,500 | $171,070108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 hematology providers in Massachusetts.
Other hematology in Boston
- Omar NadeemBoston$22.8M
- Monique Hartley-BrownBoston$5.2M
- Jacalyn RosenblattBoston$4.8M
- Shayna SarosiekBoston$4M
- Vaishali SanchorawalaBoston$2.9M
- Jerome RitzBoston$2M
- Andrew EvensBoston$1.1M
- Julie Erika HayduBoston$940K
- John SloanBoston$882K
- Salvia JainBoston$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.